- Home
- POR vs DNTH Comparison
POR vs DNTH Comparison
Compare POR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POR | DNTH |
|---|---|---|
| Founded | 1889 | 2015 |
| Country | United States | United States |
| Employees | 2915 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | POR | DNTH |
|---|---|---|
| Price | $44.14 | $78.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 17 |
| Target Price | $51.09 | ★ $140.80 |
| AVG Volume (30 Days) | ★ 2.4M | 896.9K |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $3,576,000,000.00 | $2,036,000.00 |
| Revenue This Year | $3.37 | N/A |
| Revenue Next Year | $7.63 | N/A |
| P/E Ratio | $46.00 | ★ N/A |
| Revenue Growth | ★ 3.95 | N/A |
| 52 Week Low | $43.26 | $32.28 |
| 52 Week High | $54.62 | $117.88 |
Technical Indicators
Market Signals| Indicator | POR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 36.61 |
| Support Level | $43.29 | $75.50 |
| Resistance Level | $45.72 | $91.36 |
| Average True Range (ATR) | 0.84 | 3.87 |
| MACD | 0.16 | 0.70 |
| Stochastic Oscillator | 40.04 | 52.27 |
Price Performance
Historical ComparisonAbout POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.6 gigawatts of gas, coal, wind, and hydro generation, along with 300 megawatts of energy storage. In February 2026, PGE proposed acquiring utilities in Washington state from Berkshire Hathaway Energy.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.